Helske Satu, Lindstedt Ken A, Laine Mika, Mäyränpää Mikko, Werkkala Kalervo, Lommi Jyri, Turto Heikki, Kupari Markku, Kovanen Petri T
Wihuri Research Institute, Helsinki, Finland.
J Am Coll Cardiol. 2004 Nov 2;44(9):1859-66. doi: 10.1016/j.jacc.2004.07.054.
The purpose of this study was to investigate the expression of angiotensin II (Ang II)-producing enzyme systems in normal and stenotic aortic valves.
Chronic inflammation and fibrosis are involved in the pathogenesis of aortic stenosis (AS), but the detailed molecular mechanisms of this atherosclerosis-like process remain obscure. Angiotensin II, a powerful mediator of inflammation and fibrosis, may participate in AS progression.
Stenotic aortic valves (n = 86) were obtained from patients undergoing valve replacement surgery, and control valves (n = 11) were obtained from patients undergoing cardiac transplantation. Angiotensin-converting enzyme (ACE) and mast cell (MC)-derived chymase were quantified by reverse-transcription polymerase chain reaction, autoradiography, and immunostaining. The MCs, macrophages, and T lymphocytes were detected by immunohistochemistry, and angiotensin II type 1 receptor (AT-1R) by autoradiography.
Compared with control valves, stenotic aortic valves showed a significant increase in both messenger ribonucleic acid (mRNA) (p = 0.001) and protein (p < 0.001) expression of ACE, which colocalized with macrophages. Similarly, the expression of AT-1R protein and chymase mRNA and protein was upregulated (p < 0.001), and the number of MCs was six-fold higher in stenotic than in normal valves. The MCs were associated with the calcified areas, and-in contrast to control valves-showed an increased degree of degranulation, a prerequisite for chymase secretion and action.
Angiotensin-converting enzyme and chymase, two Ang II-forming enzymes, are locally expressed in aortic valves, and owing to infiltration of macrophages and MCs, are further upregulated in stenotic valves. These novel findings, implicating chronic inflammation and an increased expression of local Ang II-forming systems, suggest that therapeutic interventions aiming at inhibiting these processes may slow AS progression.
本研究旨在调查正常和狭窄主动脉瓣中产生血管紧张素II(Ang II)的酶系统的表达情况。
慢性炎症和纤维化参与主动脉瓣狭窄(AS)的发病机制,但这种动脉粥样硬化样过程的详细分子机制仍不清楚。血管紧张素II是炎症和纤维化的强大介质,可能参与AS的进展。
从接受瓣膜置换手术的患者中获取狭窄主动脉瓣(n = 86),从接受心脏移植的患者中获取对照瓣膜(n = 11)。通过逆转录聚合酶链反应、放射自显影和免疫染色对血管紧张素转换酶(ACE)和肥大细胞(MC)衍生的糜酶进行定量。通过免疫组织化学检测MC、巨噬细胞和T淋巴细胞,通过放射自显影检测血管紧张素II 1型受体(AT-1R)。
与对照瓣膜相比,狭窄主动脉瓣中ACE的信使核糖核酸(mRNA)(p = 0.001)和蛋白质(p < 0.001)表达均显著增加,且与巨噬细胞共定位。同样,AT-1R蛋白以及糜酶mRNA和蛋白质的表达上调(p < 0.001),狭窄瓣膜中的MC数量比正常瓣膜高六倍。MC与钙化区域相关,与对照瓣膜不同的是,其脱颗粒程度增加,这是糜酶分泌和作用的前提条件。
血管紧张素转换酶和糜酶这两种生成Ang II的酶在主动脉瓣中局部表达,由于巨噬细胞和MC的浸润,在狭窄瓣膜中进一步上调。这些新发现表明慢性炎症和局部生成Ang II系统的表达增加,提示旨在抑制这些过程的治疗干预可能会减缓AS的进展。